Welcome to our dedicated page for Cingulate SEC filings (Ticker: CING), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cingulate Inc. filings document a clinical-stage biopharmaceutical issuer developing Precision Timed Release™ drug-delivery products, including CTx-1301 for ADHD, alongside its common stock and warrants listed on Nasdaq. Periodic and current reports furnish operating results, business updates, patent notices, FDA-related program disclosures and research-and-development spending context.
The filing record also covers capital-structure actions such as private placements, preferred stock, warrants, unregistered equity issuances, debt exchanges and at-the-market offering agreements. Proxy and 8-K disclosures address shareholder voting matters, Nasdaq rule compliance, board committee composition, officer appointments, employment agreements and other governance events.
Cingulate Inc. EVP and CSO Raul R. Silva received two stock option grants on July 16, 2026. One covers 53,600 shares and the other 26,400 shares of common stock at an exercise price of $4.4300 per share, expiring July 16, 2036. Both vest 25% on March 31, 2027 and then in substantially equal monthly installments over 36 months. The second grant becomes exercisable only if the issuer’s NDA for CTx-1301 is approved by the FDA during 2027; otherwise that option, including any vested portion, terminates.
Cingulate Inc. held its 2026 Annual Meeting on July 9, 2026, where stockholders approved Amendment No. 3 to the 2021 Omnibus Equity Incentive Plan, increasing shares of common stock authorized for issuance under the plan by 625,000 to a total of 2,221,126 shares.
The Board reduced its size to five directors, appointed Chief Executive Officer Shane Schaffer as chairman, and named director Jeff Hargroves as lead independent director. Committee leadership was reorganized, with Zhanpeng “Frederick” Jiang chairing the Audit Committee, Hargroves chairing the Nominating and Corporate Governance Committee, and Bryan Lawrence chairing the Compensation Committee. Stockholders elected Hargroves as a Class II director and ratified KPMG LLP as independent registered public accounting firm for 2026, while also approving but not using authority to adjourn the meeting.
Cingulate Inc. reported that EVP and CSO Raul R. Silva received a grant of stock options as part of his compensation. The award covers options for 3,885 shares of common stock at an exercise price of $5.47 per share, expiring in 2036. These options were granted pursuant to Dr. Silva's employment agreement and increase his potential equity exposure but do not represent an open-market purchase or sale.
Cingulate Inc. reported two corporate updates. Its subsidiary Cingulate Therapeutics LLC amended the employment agreement with Executive Vice President and Chief Medical Officer Matthew N. Brams, extending his full-time employment trial period from June 30, 2026 to September 30, 2026. The company also announced it has been added to the Russell 3000E® Index, which tracks the performance of approximately 4,000 of the largest investable U.S. equities and is fully reconstituted each June. The press release highlights Cingulate’s focus on its lead ADHD candidate CTx-1301 and its proprietary Precision Timed Release platform, which is designed to deliver medication in multiple timed doses over the day.
Cingulate Inc. announced issuance of a new U.S. patent protecting its lead ADHD treatment candidate CTx-1301 through December 2042. Granted as U.S. Patent No. 12,653,791, it covers key aspects of the drug’s trimodal Precision Timed Release tablet formulation and method of use.
The patent is the first U.S. patent owned wholly by Cingulate for CTx-1301 and further strengthens the company’s intellectual property around its PTR platform as it moves toward potential commercialization. Cingulate also holds related patents across 30 European territories and in Australia, Canada and Israel, with additional applications pending.
Cingulate Inc. director Thomas Jeffrey Hargroves reported multiple acquisitions of the company’s securities. Through Hargroves Family Investments, LLC, he bought 97,276 shares of common stock at $5.04 per share and 77,821 warrants at $0.10 per warrant on February 13, 2026, tied to a private placement previously described in a Form 8-K. These indirect holdings total 97,468 common shares and 77,821 warrants after the transactions, and he disclaims beneficial ownership beyond his pecuniary interest. On March 9, 2026, he also received a stock option grant for 15,000 shares of common stock at an exercise price of $6.85 per share, vesting 50% six months after grant and the remainder after twelve months, expiring in 2036.
Cingulate Inc. director Thomas Jeffrey Hargroves filed an initial Form 3 showing indirect ownership through Hargroves Family Investments, LLC. The filing reports 192 shares of common stock and a warrant to purchase 35 additional common shares at an exercise price of $1,440 per share, expiring on December 10, 2026. Footnotes note the Form 3 was delayed due to technical issues obtaining EDGAR codes and state that Hargroves disclaims beneficial ownership beyond his pecuniary interest.
Cingulate Inc. reported that the FDA has issued a Complete Response Letter for its New Drug Application for CTx-1301, a once-daily ADHD treatment. The letter centers on specific Chemistry, Manufacturing and Controls information requests and currently does not raise concerns about clinical safety or efficacy.
The company plans a prompt resubmission to address the FDA’s requests and continue pre-commercial work. Management highlights nearly $30 million in cash reserves, which they believe is enough to complete the additional CMC work, support resubmission, and fund activities into 2027.
Cingulate Inc. is asking stockholders to approve several items at its July 9, 2026 virtual annual meeting. Investors will vote on electing Jeff Hargroves as a Class II director through 2029, ratifying KPMG LLP as auditor for 2026, and expanding the 2021 Omnibus Equity Incentive Plan by 625,000 shares to a total of 2,221,126 shares. They will also consider an adjournment proposal to allow additional proxy solicitation if needed. The record date is May 18, 2026, when 13,469,036 common shares were outstanding, and detailed disclosures cover board structure, independence, committee work, executive employment terms, and 2025 compensation.